Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVIR Atea Pharmaceuticals	$3.47 -4.7%	$3.41	$2.45 ▼ $4.14	$311.51M	0.25	376,402 shs	313,746 shs
BNTC Benitec Biopharma	$10.96 +0.3%	$13.55	$7.05 ▼ $17.15	$286.92M	0.4	80,430 shs	71,260 shs
CELU Celularity	$3.12 -4.9%	$2.30	$1.00 ▼ $5.22	$78.55M	0.79	586,207 shs	71,504 shs
SGMT Sagimet Biosciences	$8.25 -5.1%	$7.64	$1.73 ▼ $11.41	$266.56M	3.36	784,120 shs	826,826 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVIR Atea Pharmaceuticals	-4.67%	-11.03%	-4.41%	+16.44%	-9.16%
BNTC Benitec Biopharma	+0.27%	-1.97%	-13.97%	-27.18%	+24.26%
CELU Celularity	-4.88%	+5.41%	+53.69%	+95.61%	-0.95%
SGMT Sagimet Biosciences	-5.06%	-19.43%	+1.73%	+115.40%	+145.54%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVIR Atea Pharmaceuticals	1.6726 of 5 stars	3.3	0.0	0.6	2.5	1.3
BNTC Benitec Biopharma	1.5705 of 5 stars	3.6	0.0	3.4	0.8	0.0
CELU Celularity	0.2335 of 5 stars	0.0	1.0	2.0	1.7	0.0
SGMT Sagimet Biosciences	2.7746 of 5 stars	3.5	4.0	1.5	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVIR Atea Pharmaceuticals	2.50	Moderate Buy	$6.00	72.91% Upside
BNTC Benitec Biopharma	3.13	Buy	$26.00	137.23% Upside
CELU Celularity	0.00	N/A	N/A	N/A
SGMT Sagimet Biosciences	3.00	Buy	$26.83	225.25% Upside

Current Analyst Ratings Breakdown

Latest CELU, BNTC, SGMT, and AVIR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/24/2025	SGMT Sagimet Biosciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$28.00
7/7/2025	BNTC Benitec Biopharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
6/6/2025	SGMT Sagimet Biosciences	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $27.00
5/19/2025	BNTC Benitec Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
5/15/2025	BNTC Benitec Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$20.00 ➝ $20.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	$5.20 per share	N/A
BNTC Benitec Biopharma	$80K	3,596.25	N/A	N/A	$4.68 per share	2.34
CELU Celularity	$54.22M	1.38	N/A	N/A	$0.37 per share	8.43
SGMT Sagimet Biosciences	$2M	126.51	N/A	N/A	$5.08 per share	1.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVIR Atea Pharmaceuticals	-$168.38M	-$1.65	N/A	N/A	N/A	N/A	-31.26%	-29.27%	8/7/2025 (Estimated)
BNTC Benitec Biopharma	-$21.75M	-$1.51	N/A	N/A	N/A	N/A	-38.26%	-35.71%	9/25/2025 (Estimated)
CELU Celularity	-$57.89M	-$2.65	N/A	∞	N/A	-106.77%	-271.88%	-42.82%	8/7/2025 (Estimated)
SGMT Sagimet Biosciences	-$45.57M	-$1.76	N/A	N/A	N/A	N/A	-35.21%	-34.09%	8/13/2025 (Estimated)

Latest CELU, BNTC, SGMT, and AVIR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	SGMT Sagimet Biosciences	-$0.57	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	AVIR Atea Pharmaceuticals	-$0.44	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q3 2025	BNTC Benitec Biopharma	-$0.36	-$0.24	+$0.12	-$0.24	N/A	N/A
5/12/2025	Q1 2025	AVIR Atea Pharmaceuticals	-$0.56	-$0.40	+$0.16	-$0.40	N/A	N/A
5/8/2025	Q4 2024	CELU Celularity	-$1.50	-$0.59	+$0.91	-$0.59	$5.20 million	$18.13 million
5/8/2025	Q1 2025	SGMT Sagimet Biosciences	-$0.79	-$0.56	+$0.23	-$0.56	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
CELU Celularity	N/A	N/A	N/A	N/A	N/A
SGMT Sagimet Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVIR Atea Pharmaceuticals	N/A	19.94	19.94
BNTC Benitec Biopharma	0.01	14.80	14.80
CELU Celularity	4.07	0.38	0.28
SGMT Sagimet Biosciences	N/A	20.34	20.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVIR Atea Pharmaceuticals	86.67%
BNTC Benitec Biopharma	52.19%
CELU Celularity	19.02%
SGMT Sagimet Biosciences	87.86%

Insider Ownership

Company	Insider Ownership
AVIR Atea Pharmaceuticals	18.10%
BNTC Benitec Biopharma	1.30%
CELU Celularity	22.10%
SGMT Sagimet Biosciences	14.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVIR Atea Pharmaceuticals	70	85.58 million	70.09 million	Optionable
BNTC Benitec Biopharma	20	26.25 million	25.91 million	No Data
CELU Celularity	220	23.95 million	18.66 million	Optionable
SGMT Sagimet Biosciences	8	30.67 million	26.17 million	Optionable

CELU, BNTC, SGMT, and AVIR Headlines

Recent News About These Companies

Analysts Set Sagimet Biosciences Inc. (NASDAQ:SGMT) PT at $26.83

July 29, 2025 | americanbankingnews.com

Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Recommendation of "Buy" by Analysts

July 26, 2025 | marketbeat.com

Sagimet Biosciences (NASDAQ:SGMT) Coverage Initiated at Canaccord Genuity Group

July 25, 2025 | marketbeat.com

David Happel Sells 65,478 Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT) Stock

July 25, 2025 | americanbankingnews.com

Sagimet gains as Canaccord Genuity starts with Buy on potential against MASH

July 24, 2025 | msn.com

Sagimet Biosciences Inc. (NASDAQ:SGMT) Insider Eduardo Bruno Martins Sells 8,277 Shares

July 24, 2025 | marketbeat.com

Insider Selling: Sagimet Biosciences Inc. (NASDAQ:SGMT) General Counsel Sells 10,780 Shares of Stock

July 24, 2025 | marketbeat.com

Insider Selling: Sagimet Biosciences Inc. (NASDAQ:SGMT) CEO Sells 65,478 Shares of Stock

July 24, 2025 | marketbeat.com

Insider Selling: Sagimet Biosciences Inc. (NASDAQ:SGMT) Insider Sells 8,277 Shares of Stock

July 24, 2025 | insidertrades.com

Sagimet Biosciences (NASDAQ:SGMT) Trading Up 8.7% - Here's Why

July 23, 2025 | marketbeat.com

We Think Sagimet Biosciences (NASDAQ:SGMT) Can Afford To Drive Business Growth

July 16, 2025 | finance.yahoo.com

SGMT Sagimet Biosciences Inc. - Seeking Alpha

June 28, 2025 | seekingalpha.com

Sagimet Biosciences Inc News (SGMT) - Investing.com

June 27, 2025 | investing.com

Sagimet Biosciences Inc. (SGMT) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Sagimet Biosciences Inc.

June 14, 2025 | wsj.com

Sagimet Biosciences updates executive compensation

June 12, 2025 | investing.com

What Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now?

June 11, 2025 | zacks.com

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to ...

June 11, 2025 | morningstar.comM

Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should Know

June 9, 2025 | zacks.com

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025

June 9, 2025 | globenewswire.com

Sagimet Biosciences Analyst Ratings

June 5, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELU, BNTC, SGMT, and AVIR Company Descriptions

Atea Pharmaceuticals NASDAQ:AVIR

$3.47 -0.17 (-4.67%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$3.48 +0.00 (+0.14%)

As of 08/1/2025 04:10 PM Eastern

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Benitec Biopharma NASDAQ:BNTC

$10.96 +0.03 (+0.27%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$10.96 -0.01 (-0.05%)

As of 08/1/2025 04:04 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Celularity NASDAQ:CELU

$3.12 -0.16 (-4.88%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$3.13 +0.01 (+0.32%)

As of 08/1/2025 07:19 PM Eastern

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

Sagimet Biosciences NASDAQ:SGMT

$8.25 -0.44 (-5.06%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$8.39 +0.14 (+1.68%)

As of 08/1/2025 05:49 PM Eastern

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time